A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model

Gang Li, Samita Andreansky, Gustavo Helguera, Marjan Sepassi, Nona Janikashvili, Jessica Cantrell, Collin L. LaCasse, Nicolas Larmonier, Manuel L. Penichet, Emmanuel Katsanis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4+ T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

Original languageEnglish
Pages (from-to)721-729
Number of pages9
JournalMolecular Cancer Therapeutics
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Humoral Immunity
Vaccines
Breast Neoplasms
Neoplasms
Proteins
T-Lymphocytes
B-Lymphocytes
Antibody-Dependent Cell Cytotoxicity
Cancer Vaccines
Cellular Immunity
Immunotherapy
Antibody Formation
Serum

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. / Li, Gang; Andreansky, Samita; Helguera, Gustavo; Sepassi, Marjan; Janikashvili, Nona; Cantrell, Jessica; LaCasse, Collin L.; Larmonier, Nicolas; Penichet, Manuel L.; Katsanis, Emmanuel.

In: Molecular Cancer Therapeutics, Vol. 7, No. 3, 01.03.2008, p. 721-729.

Research output: Contribution to journalArticle

Li, G, Andreansky, S, Helguera, G, Sepassi, M, Janikashvili, N, Cantrell, J, LaCasse, CL, Larmonier, N, Penichet, ML & Katsanis, E 2008, 'A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model', Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 721-729. https://doi.org/10.1158/1535-7163.MCT-07-2067
Li, Gang ; Andreansky, Samita ; Helguera, Gustavo ; Sepassi, Marjan ; Janikashvili, Nona ; Cantrell, Jessica ; LaCasse, Collin L. ; Larmonier, Nicolas ; Penichet, Manuel L. ; Katsanis, Emmanuel. / A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 3. pp. 721-729.
@article{844e6a8419f84d328e0a9c2f5b32e606,
title = "A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model",
abstract = "We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4+ T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.",
author = "Gang Li and Samita Andreansky and Gustavo Helguera and Marjan Sepassi and Nona Janikashvili and Jessica Cantrell and LaCasse, {Collin L.} and Nicolas Larmonier and Penichet, {Manuel L.} and Emmanuel Katsanis",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-07-2067",
language = "English",
volume = "7",
pages = "721--729",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model

AU - Li, Gang

AU - Andreansky, Samita

AU - Helguera, Gustavo

AU - Sepassi, Marjan

AU - Janikashvili, Nona

AU - Cantrell, Jessica

AU - LaCasse, Collin L.

AU - Larmonier, Nicolas

AU - Penichet, Manuel L.

AU - Katsanis, Emmanuel

PY - 2008/3/1

Y1 - 2008/3/1

N2 - We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4+ T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

AB - We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4+ T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

UR - http://www.scopus.com/inward/record.url?scp=41649097149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649097149&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-2067

DO - 10.1158/1535-7163.MCT-07-2067

M3 - Article

C2 - 18347157

AN - SCOPUS:41649097149

VL - 7

SP - 721

EP - 729

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -